nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.10.2021 | Neurology of Systemic Diseases (J. Biller, Section Editor)

Neurological Complications of Pulmonary Embolism: a Literature Review

verfasst von: Parth V. Desai, Nicolas Krepostman, Matthew Collins, Sovik De Sirkar, Alexa Hinkleman, Kevin Walsh, Jawed Fareed, Amir Darki

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The present review discusses in-depth about neurological complications following acute venous thromboembolism (VTE).

Recent Findings

Intracranial hemorrhage, acute ischemic cerebrovascular events, and VTE in brain tumors are described as central nervous system (CNS) complications of PE, while peripheral neuropathy and neuropathic pain are reported as peripheral nervous system (PNS) sequelae of PE. Syncope and seizure are illustrated as atypical neurological presentations of PE.

Summary

Mounting evidence suggests higher risk of venous thromboembolism (VTE) in patients with neurological diseases, but data on reverse, i.e., neurological sequelae following VTE, is underexplored. The present review is an attempt to explore some of the latter issues categorized into CNS, PNS, and atypical complications following VTE.

Wendelboe AM, Raskob GE. Global burden of thrombosis: Epidemiologic aspects. Circ Res. 2016;118:1340–7. Available from: https://doi.org/10.1161/CIRCRESAHA.115.306841.

Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38:S495–501. Available from: https://doi.org/10.1016/j.amepre.2009.12.017.

Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016;137:3–10. Available from: https://doi.org/10.1016/j.thromres.2015.11.033.

Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143:180–90. Available from: https://doi.org/10.1111/j.1365-2141.2008.07323.x.

Rinde LB, Småbrekke B, Mathiesen EB, Løchen M-L, Njølstad I, Hald EM, et al. Ischemic Stroke and Risk of Venous Thromboembolism in the General Population: The Tromsø Study. J Am Heart Assoc. 2016;5. Available from: https://doi.org/10.1161/JAHA.116.004311.

Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med. 2011;364:861–9. Available from: https://doi.org/10.1056/NEJMcp1008740.

Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing G-J, Kyrle PA, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14:1480–3. Available from: https://doi.org/10.1111/jth.13336.

Moheimani F, Jackson DE. Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol. 2011;2011:124610. Available from: https://doi.org/10.5402/2011/124610.

Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:287S–310S. Available from: https://doi.org/10.1378/chest.126.3_suppl.287S.

10.

Ho WK. Deep vein thrombosis--risks and diagnosis. Aust Fam Physician. 2010;39:468–74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20628659.

11.

Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ. 2006;175:1087–92. Available from: https://doi.org/10.1503/cmaj.060366.

12.

Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107:I22–30. Available from: https://doi.org/10.1161/01.CIR.0000078464.82671.78.

13.

Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007;146:204–10. Available from: https://doi.org/10.7326/0003-4819-146-3-200702060-00149.

14.

Kahn SR. The post thrombotic syndrome. Thromb Res. 2011;127 Suppl 3:S89–92. Available from: https://doi.org/10.1016/S0049-3848(11)70024-X.

15.

Winter M-P, Schernthaner GH, Lang IM. Chronic complications of venous thromboembolism. J Thromb Haemost. 2017;15:1531–40. Available from: https://doi.org/10.1111/jth.13741.

16.

Wilbur J, Shian B. Deep venous thrombosis and pulmonary embolism: Current therapy. Am Fam Physician. 2017;95:295–302. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28290648.

17.

Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the american heart association. Circulation. 2011. Available from: https://doi.org/10.1161/CIR.0b013e318214914f.

18.

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016. Available from: https://doi.org/10.1016/j.chest.2015.11.026.

19.

Becattini C, Agnelli G. Risk stratification and management of acute pulmonary embolism. Hematology Am Soc Hematol Educ Program. 2016;2016:404–12. Available from: https://doi.org/10.1182/asheducation-2016.1.404.

20.

Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:1041–6. Available from: https://doi.org/10.1164/rccm.200506-862OC.

21.

Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:1383–9. Available from: https://doi.org/10.1001/archinternmed.2010.199.

22.

Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009;102:688–93. Available from: https://doi.org/10.1160/TH09-04-0266.

23.

Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:789–96. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18989522.

24.

Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke. 2012. Available from: https://doi.org/10.1161/STROKEAHA.112.650614.

25.

Poon MTC, Fonville AF, Salman RAS. Long-term prognosis after intracerebral haemorrhage: Systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014. Available from: https://doi.org/10.1136/jnnp-2013-306476.

26.

Daley MJ, Murthy MS, Peterson EJ. Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: Scope of the problem. Ther Adv Drug Saf. 2015. Available from: https://doi.org/10.1177/2042098615572333.

27.

Klok FA, Kooiman J, Huisman MV, Konstantinides S, Lankeit M. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: A clinically oriented review. Eur Respir J. 2015. Available from: https://doi.org/10.1183/09031936.00040714.

28.

Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014. Available from: https://doi.org/10.1093/eurheartj/ehu283.

29.

Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016. Available from: https://doi.org/10.1016/S0140-6736(16)30514-1.

30.

•• Wolfe Z, Khan SU, Nasir F, Raghu Subramanian C, Lash B. A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J Thromb Haemost. 2018. Available from: https://doi.org/10.1111/jth.14131. A meta-analysis comparing risk of ICH between various newer anticoagulants.

31.

Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. PREPIC 2 (2015; JAMA) IVC filters for high-risk PE. JAMA. 2015.

32.

Martin C, Sobolewski K, Bridgeman P, Boutsikaris D. Systemic thrombolysis for pulmonary embolism: A review. P T. 2016;41:770–5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27990080.

33.

Vedantham S, Piazza G, Sista AK, Goldenberg NA. Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016. Available from: https://doi.org/10.1007/s11239-015-1318-z.

34.

Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis. JAMA. 2014. Available from: https://doi.org/10.1001/jama.2014.5990.

35.

Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: Frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest. 2009; Available from: 10.1378/chest.08-2988

36.

Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes García M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis. 1995. Available from: https://doi.org/10.1007/BF01062714.

37.

Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98:1473–9. Available from: https://doi.org/10.1378/chest.98.6.1473.

38.

Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest. 1994;106:718–24. Available from: https://doi.org/10.1378/chest.106.3.718.

39.

Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest. 1994;106:712–7. Available from: https://doi.org/10.1378/chest.106.3.712.

40.

Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014. Available from: https://doi.org/10.1161/CIRCULATIONAHA.113.005544.

41.

PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA. 1990;263:2753–9. Available from: https://doi.org/10.1001/jama.1990.03440200057023.

42.

Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137:254–62. Available from: https://doi.org/10.1378/chest.09-0765.

43.

Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the “mOPETT” Trial). Am J Cardiol. 2013. Available from: https://doi.org/10.1016/j.amjcard.2012.09.027.

44.

Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999;138:39–44. Available from: https://doi.org/10.1016/s0002-8703(99)70243-7.

45.

Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507–11. Available from: https://doi.org/10.1016/0140-6736(93)90274-k.

46.

Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol. 1992;19:239–45. Available from: https://doi.org/10.1016/0735-1097(92)90472-y.

47.

Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143–50. Available from: https://doi.org/10.1056/NEJMoa021274.

48.

Mühl D, Füredi R, Gecse K, Ghosh S, Falusi B, Bogár L, et al. Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism. Blood Coagul Fibrinolysis. 2007;18:661–7. Available from: https://doi.org/10.1097/MBC.0b013e3282e38e61.

49.

Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011;341:33–9. Available from: https://doi.org/10.1097/MAJ.0b013e3181f1fc3e.

50.

Patra S, Agrawal N, Manjunath CN, Nagesh CM, Srinivas BC, Ravindranath KS, et al. Thrombolytic therapy in the treatment of acute sub-massive pulmonary embolism: a prospective observational study. Blood Coagul Fibrinolysis. 2014;25:167–71. Available from: https://doi.org/10.1097/MBC.0000000000000015.

51.

Goldhaber SZ, Kessler CM, Heit JA, Elliott CG, Friedenberg WR, Heiselman DE, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992;20:24–30. Available from: https://doi.org/10.1016/0735-1097(92)90132-7.

52.

Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: A systematic review and a meta-analysis. J Thromb Haemost. 2010. Available from: https://doi.org/10.1111/j.1538-7836.2010.03777.x.

53.

Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–11. Available from: https://doi.org/10.1056/NEJMoa1302097.

54.

Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12:459–68. Available from: https://doi.org/10.1111/jth.12521.

55.

Stein PD, Matta F, Keyes DC, Willyerd GL. Impact of Vena Cava Filters on in-Hospital case fatality rate from pulmonary embolism. Am J Med. 2012. Available from: https://doi.org/10.1016/j.amjmed.2011.05.025.

56.

Izcovich A, Criniti JM, Popoff F, Lu L, Wu J, Ageno W, et al. Thrombolytics for venous thromboembolic events: A systematic review with meta-analysis. Blood Adv. 2020. Available from: https://doi.org/10.1182/bloodadvances.2020001513.

57.

Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med. 2014. Available from: https://doi.org/10.1056/nejmoa1302097.

58.

Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: A meta-analysis of the randomized controlled trials. Circulation. 2004. Available from: https://doi.org/10.1161/01.CIR.0000137826.09715.9C.

59.

Brandt K, McGinn K, Quedado J. Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism. Ann Pharmacother. 2015. Available from: https://doi.org/10.1177/1060028015579988.

60.

Zhang Z, Zhai ZG, Liang LR, Liu FF, Yang YH, Wang C. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysis. Thromb Res. 2014. Available from: https://doi.org/10.1016/j.thromres.2013.12.026.

61.

Dudzinski DM, Giri J, Rosenfield K. Interventional Treatment of Pulmonary Embolism. Circ Cardiovasc Interv. 2017. Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.116.004345.

62.

Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv. 2015. Available from: https://doi.org/10.1016/j.jcin.2015.04.020.

63.

• Chiarello MA, Sista AK. Catheter-Directed Thrombolysis for Submassive Pulmonary Embolism. Semin Intervent Radiol. 2018. Available from: https://doi.org/10.1055/s-0038-1642041. This review describes clinical presentation of submissive PE and role for catheter directed thrombolysis.

64.

Kuo WT, Banerjee A, Kim PS, De Marco FJ, Levy JR, Facchini FR, et al. Pulmonary embolism response to fragmentation, embolectomy, and catheter thrombolysis (PERFECT): Initial results from a prospective multicenter registry. Chest. 2015. Available from: https://doi.org/10.1378/chest.15-0119.

65.

Scherz N, Méan M, Limacher A, Righini M, Jaeger K, Beer HJ, et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost. 2013. Available from: https://doi.org/10.1111/jth.12111.

66.

Brown JD, Goodin AJ, Lip GYH, Adams VR. Risk stratification for bleeding complications in patients with venous thromboembolism: Application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment. J Am Heart Assoc. 2018; Available from: https://doi.org/10.1161/JAHA.117.007901.

67.

Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AWA, et al. An Association between Atherosclerosis and Venous Thrombosis. N Engl J Med. 2003. Available from: https://doi.org/10.1056/nejmoa022157.

68.

Srensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007. Available from: https://doi.org/10.1016/S0140-6736(07)61745-0.

69.

Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation. 2008. Available from: https://doi.org/10.1161/CIRCULATIONAHA.107.709204.

70.

Madridano O, Del Toro J, Lorenzo A, Martín M, Gómez Cerezo J, Hernández L, et al. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. J Vasc Surg: Venous Lymphat Disord. 2015. Available from: https://doi.org/10.1016/j.jvsv.2014.11.002.

71.

• Koutroulou I, Tsivgoulis G, Tsalikakis D, Karacostas D, Grigoriadis N, Karapanayiotides T. Epidemiology of patent foramen ovale in general population and in stroke patients: A narrative review. Front Neurol. 2020;11:281. Available from: https://doi.org/10.3389/fneur.2020.00281. This review described the prevalence of PFO in general population and stroke patients and emphasized that it should not be underestimated.

72.

Greenberg JW, Goff ZD, Mooser AC, Wittgen CM, Smeds MR. Acute Limb Ischemia Secondary to Patent Foramen Ovale-Mediated Paradoxical Embolism: A Case Report and Systematic Review of the Literature. Ann Vasc Surg. 2020;66:668.e5-668.e10. Available from: https://doi.org/10.1016/j.avsg.2019.12.022.

73.

Zafar H, Anderson L, Cox AT, Bastiaenen R. Pulmonary embolism and infarction with a paradoxical thrombus visualised in both atria. BMJ Case Rep. 2018;2018. Available from: https://doi.org/10.1136/bcr-2018-225195.

74.

Nuñez R, Sanchez JA, Berber S, Loaiza F, Nuñez JG, Arias S, et al. Case report: Thrombus in transit—a cause of impending paradoxical embolism. Eur Heart J - Case Rep. Oxford Academic; 2021 [cited 2021 Mar 28];5. Available from: https://academic.oup.com/ehjcr/article/5/2/ytaa580/6138215.

75.

Allport LE, Butcher KS. Thrombolysis for concomitant acute stroke and pulmonary embolism. J Clin Neurosci. 2008;15:917–20. Available from: https://doi.org/10.1016/j.jocn.2007.03.026.

76.

Barros-Gomes S, El Sabbagh A, Eleid MF, Mankrad SV. Concomitant acute stroke, pulmonary and myocardial infarction due to in-transient thrombus across a patent foramen ovale. Echo Res Pract. 2018;5:I9–10. Available from: https://doi.org/10.1530/ERP-18-0044.

77.

Lak HM, Ahmed T, Nair R, Maroo A. Simultaneous multifocal paradoxical embolism in an elderly patient with patent foramen ovale: A case report. Cureus. 2020;12:e6992. Available from: https://doi.org/10.7759/cureus.6992.

78.

Lapostolle F, Borron SW, Surget V, Sordelet D, Lapandry C, Adnet F. Stroke associated with pulmonary embolism after air travel. Neurology. 2003;60:1983–5. Available from: https://doi.org/10.1212/01.wnl.0000068025.97902.28.

79.

•• Lio KU, Jiménez D, Moores L, Rali P. Clinical conundrum: concomitant high-risk pulmonary embolism and acute ischemic stroke. Emerg Radiol. 2020;27:433–9. Available from: https://doi.org/10.1007/s10140-020-01772-7. A descriptive literature review of presentation, treatment and prognosis of high-risk PE and acute ischemic stroke.

80.

Naidoo P, Hift R. Massive pulmonary thromboembolism and stroke. Case Rep Med. 2011;2011:398571. Available from: https://doi.org/10.1155/2011/398571.

81.

Pavesi PC, Pedone C, Crisci M, Piacentini A, Fulvi M, Di Pasquale G. Concomitant submassive pulmonary embolism and paradoxical embolic stroke after a long flight: which is the optimal treatment? J Cardiovasc Med. 2008;9:1070–3. Available from: https://doi.org/10.2459/JCM.0b013e328306f2ea.

82.

• Vindiš D, Hutyra M, Šaňák D, Král M, Čecháková E, Littnerová S, et al. Patent Foramen Ovale and the Risk of Cerebral Infarcts in Acute Pulmonary Embolism-A Prospective Observational Study. J Stroke Cerebrovasc Dis. 2018;27:357–64. Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.004. This observational study describes the prevalence of PFO and risk of stroke in patients with PE.

83.

Zhang H-Y, Zhang Y, Cao Y-J, Mei L-L, Zhang X, Wu Z-G, et al. Acute inferior ST-segment elevation myocardial infarction and previous cryptogenic stroke caused by a paradoxical embolism with a concomitant pulmonary embolism. J Geriatr Cardiol. 2017;14:421–4. Available from: https://doi.org/10.11909/j.issn.1671-5411.2017.06.003.

84.

Doyen D, Castellani M, Moceri P, Chiche O, Lazdunski R, Bertora D, et al. Patent foramen ovale and stroke in intermediate-risk pulmonary embolism. Chest. 2014;146:967–73. Available from: https://doi.org/10.1378/chest.14-0100.

85.

Goliszek S, Wiśniewska M, Kurnicka K, Lichodziejewska B, Ciurzyński M, Kostrubiec M, et al. Patent foramen ovale increases the risk of acute ischemic stroke in patients with acute pulmonary embolism leading to right ventricular dysfunction. Thromb Res. 2014;134:1052–6. Available from: https://doi.org/10.1016/j.thromres.2014.09.013.

86.

Clergeau M-R, Hamon M, Morello R, Saloux E, Viader F, Hamon M. Silent cerebral infarcts in patients with pulmonary embolism and a patent foramen ovale: a prospective diffusion-weighted MRI study. Stroke. 2009;40:3758–62. Available from: https://doi.org/10.1161/STROKEAHA.109.559898.

87.

Windecker S, Stortecky S, Meier B. Paradoxical embolism. J Am Coll Cardiol. 2014;64:403–15. Available from: https://doi.org/10.1016/j.jacc.2014.04.063.

88.

Mojadidi MK, Christia P, Salamon J, Liebelt J, Zaman T, Gevorgyan R, et al. Patent foramen ovale: Unanswered questions. Eur J Intern Med. 2015;26:743–51. Available from: https://doi.org/10.1016/j.ejim.2015.09.017.

89.

Ueno Y, Shimada Y, Tanaka R, Miyamoto N, Tanaka Y, Hattori N, et al. Patent foramen ovale with atrial septal aneurysm may contribute to white matter lesions in stroke patients. Cerebrovasc Dis. 2010;30:15–22. Available from: https://doi.org/10.1159/000313439.

90.

•• Le Moigne E, Timsit S, Ben Salem D, Didier R, Jobic Y, Paleiron N, et al. Patent foramen ovale and ischemic stroke in patients with pulmonary embolism: A prospective cohort study. Ann Intern Med. 2019;170:756–63. Available from: https://doi.org/10.7326/M18-3485. One of the largest prospective study evaluating the risk of stroke in patients with PFO and symptomatic PE suggesting the importance of paradoxical embolism.

91.

Saric M, Armour AC, Arnaout MS, Chaudhry FA, Grimm RA, Kronzon I, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr. 2016;29:1–42. Available from: https://doi.org/10.1016/j.echo.2015.09.011.

92.

Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, et al. Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation. Health Technol Assess. 2014;18:1–176. Available from: https://doi.org/10.3310/hta18160.

93.

Powers WJ. Clinical utility of echocardiography in secondary ischemic stroke prevention. Handb Clin Neurol. 2021;177:359–75. Available from: https://doi.org/10.1016/B978-0-12-819814-8.00022-6.

94.

Rodrigues AC, Picard MH, Carbone A, Arruda AL, Flores T, Klohn J, et al. Importance of adequately performed Valsalva maneuver to detect patent foramen ovale during transesophageal echocardiography. J Am Soc Echocardiogr. 2013;26:1337–43. Available from: https://doi.org/10.1016/j.echo.2013.07.016.

95.

•• Zietz A, Sutter R, De Marchis GM. Deep vein thrombosis and pulmonary embolism among patients with a cryptogenic stroke linked to patent foramen ovale-A review of the literature. Front Neurol. 2020;11:336. Available from: https://doi.org/10.3389/fneur.2020.00336. A literature review correlating the DVT, PE and PFO to Cryptogenic stroke.

96.

Kim BJ, Sohn H, Sun BJ, Song J-K, Kang D-W, Kim JS, et al. Imaging characteristics of ischemic strokes related to patent foramen ovale. Stroke. 2013;44:3350–6. Available from: https://doi.org/10.1161/STROKEAHA.113.002459.

97.

Hart RG, Diener H-C, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429–38. Available from: https://doi.org/10.1016/S1474-4422(13)70310-7.

98.

Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47:440–5. Available from: https://doi.org/10.1016/j.jacc.2005.10.044.

99.

Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–8. Available from: https://doi.org/10.1056/NEJMoa071422.

100.

Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148–52. Available from: https://doi.org/10.1056/NEJM198805053181802.

101.

Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461–5. Available from: https://doi.org/10.7326/0003-4819-117-6-461.

102.

Ozdemir AO, Tamayo A, Munoz C, Dias B, Spence JD. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J Neurol Sci. 2008;275:121–7. Available from: https://doi.org/10.1016/j.jns.2008.08.018.

103.

Schneck MJ. Neurologic complications of venous thromboembolism. Handb Clin Neurol. 2021;177:261–7. Available from: https://doi.org/10.1016/B978-0-12-819814-8.00017-2.

104.

Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017;377:1022–32. Available from: https://doi.org/10.1056/NEJMoa1610057.

105.

Mas J-L, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017;377:1011–21. Available from: https://doi.org/10.1056/NEJMoa1705915.

106.

Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017;377:1033–42. Available from: https://doi.org/10.1056/NEJMoa1707404.

107.

• Shah R, Nayyar M, Jovin IS, Rashid A, Bondy BR, Fan T-HM, et al. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: A systematic review and meta-analysis. Ann Intern Med. 2018;168:335–42. Available from: https://doi.org/10.7326/M17-2679. This systematic review and meta-analysis concluded that in patients with PFO and cryptogenic stroke, transcatheter device closure decreases risk for recurrent stroke compared with medical therapy alone.

108.

Stevkova Z, Krastev G, Mako M, Haring J, Benova L, Zajickova I, et al. May-thurner syndrome - Analysis of the group of the patients. Cerebrovasc Dis. 2014;37.

109.

• Harbin MM, Lutsey PL. May-Thurner syndrome: History of understanding and need for defining population prevalence. J Thromb Haemost. 2020. Available from: https://doi.org/10.1111/jth.14707. This article emphasizes that the contribution of MTS to the development of DVT is likely undervalued in the setting of other more easily recognizable risk factors and difficulties surrounding diagnosis of MTS.

110.

Kiernan TJ, Yan BP, Cubeddu RJ, Rengifo-Moreno P, Gupta V, Inglessis I, et al. May-Thurner syndrome in patients with cryptogenic stroke and patent foramen ovale: an important clinical association. Stroke. 2009;40:1502–4. Available from: https://doi.org/10.1161/STROKEAHA.108.527366.

111.

Prabhakar AM, Misono AS, Brinegar KN, Khademhosseini A, Oklu R. Use of Magnetic Resonance Venography in Screening Patients With Cryptogenic Stroke for May-Thurner Syndrome. Curr Probl Diagn Radiol. 2016;45:370–2. Available from: https://doi.org/10.1067/j.cpradiol.2016.04.006.

112.

COVID-19 Map - Johns Hopkins Coronavirus Resource Center. [cited 2021 Apr 3]. Available from: https://coronavirus.jhu.edu/map.html.

113.

Piazza G, Morrow DA. Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA. 2020;324:2548–9. Available from: https://doi.org/10.1001/jama.2020.23422.

114.

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7. Available from: https://doi.org/10.1016/j.thromres.2020.04.013.

115.

• Siow I, Lee KS, Zhang JJY, Saffari SE, Ng A, Young B. Stroke as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes and predictors: Stroke and COVID-19. J Stroke Cerebrovasc Dis. 2021;30. Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105549. This review described the epidemiology and clinical outcomes of patients who suffered a stroke as a complication of Covid-19.

116.

Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res. 2020;11:322–5. Available from: https://doi.org/10.1007/s12975-020-00818-9.

117.

Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc. 2005;293. Available from: https://doi.org/10.1001/jama.293.6.715.

118.

Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015;135. Available from: https://doi.org/10.1016/S0049-3848(15)50432-5.

119.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers. 2018. Available from: https://doi.org/10.3390/cancers10100380.

120.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70. Available from: https://doi.org/10.1016/j.jacc.2017.06.047.

121.

• Bao L, Zhang S, Gong X, Cui G. Trousseau syndrome related cerebral infarction: clinical manifestations, laboratory findings and radiological features. J Stroke Cerebrovasc Dis. 2020;29. Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104891. Patients with cerebral infarcts secondary to Trousseau syndrome usually have a more severe neurologic deficit at the onset of stroke and worse clinical outomes.

122.

Umemura T, Yamamoto J, Akiba D, Nishizawa S. Bilateral cerebral embolism as a characteristic feature of patients with Trousseau syndrome. J Clin Neurosci. 2017;42. Available from: https://doi.org/10.1016/j.jocn.2017.04.014.

123.

Finelli PF, Nouh A. Three-Territory DWI acute infarcts: Diagnostic value in cancer-Associated hypercoagulation stroke (trousseau syndrome). AJNR Am J Neuroradiol. 2016;37. Available from: https://doi.org/10.3174/ajnr.A4846.

124.

Nouh AM, Staff, Ilene, Finelli PF. Three territory sign: An MRI marker of malignancy-related ischemic stroke (Trousseau syndrome). Neurol Clin Pract. 2019;9. Available from: https://doi.org/10.1212/CPJ.0000000000000603.

125.

Okazaki K, Oka F, Ishihara H, Suzuki M. Cerebral infarction associated with benign mucin-producing adenomyosis: Report of two cases. BMC Neurol. 2018;18. Available from: https://doi.org/10.1186/s12883-018-1169-2.

126.

Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res: Clin Haematol. 2009. Available from: https://doi.org/10.1016/j.beha.2008.12.001.

127.

Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. PLoS Med. 2012. Available from: https://doi.org/10.1371/journal.pmed.1001275.

128.

Riedl J, Preusser M, Nazari PMS, Posch F, Panzer S, Marosi C, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129. Available from: https://doi.org/10.1182/blood-2016-06-720714.

129.

•• Riedl J, Ay C. Venous thromboembolism in brain tumors: Risk factors, molecular mechanisms, and clinical challenges. Semin Thromb Hemost. 2019;45. Available from: https://doi.org/10.1055/s-0039-1688493. Brain tumors with the wild-type IDH1 gene express podoplanin that stimulates platelet activation and triggers venous thrombosis.

130.

Mir Seyed Nazari P, Riedl J, Preusser M, Posch F, Thaler J, Marosi C, et al. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. J Thromb Haemost. 2018;16. Available from: https://doi.org/10.1111/jth.14129.

131.

Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review. Cancer. 2000;89. Available from: https://doi.org/10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E.

132.

Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9. Available from: https://doi.org/10.1215/15228517-2006-035.

133.

Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO Blood Group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004. Available from: https://doi.org/10.1002/cncr.20150.

134.

Semrad TJ, O’Donnell R, Wun T, Chew H, Harvey D, Zhou H, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106. Available from: https://doi.org/10.3171/jns.2007.106.4.601.

135.

Castelli R, Tarsia P, Tantardini C, Pantaleo G, Guariglia A, Porro F. Syncope in patients with pulmonary embolism: comparison between patients with syncope as the presenting symptom of pulmonary embolism and patients with pulmonary embolism without syncope. Vasc Med. 2003;8:257–61. Available from: https://doi.org/10.1191/1358863x03vm510oa.

136.

Mark AL. The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol. 1983;1:90–102. Available from: https://doi.org/10.1016/s0735-1097(83)80014-x.

137.

Aviado DM, Guevara Aviado D. The Bezold-Jarisch reflex. A historical perspective of cardiopulmonary reflexes. Ann N Y Acad Sci. 2001;940:48–58. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11458703.

138.

Sanchez O, Trinquart L, Caille V, Couturaud F, Pacouret G, Meneveau N, et al. Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. Am J Respir Crit Care Med. 2010;181:168–73. Available from: https://doi.org/10.1164/rccm.200906-0970OC.

139.

Jiménez D, Aujesky D, Moores L, Gómez V, Martí D, Briongos S, et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax. 2011;66:75–81. Available from: https://doi.org/10.1136/thx.2010.150656.

140.

Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J. 2014;44:694–703. Available from: https://doi.org/10.1183/09031936.00006114.

141.

Hobohm L, Hellenkamp K, Hasenfuß G, Münzel T, Konstantinides S, Lankeit M. Comparison of risk assessment strategies for not-high-risk pulmonary embolism. Eur Respir J. 2016;47:1170–8. Available from: https://doi.org/10.1183/13993003.01605-2015.

142.

Altınsoy B, Erboy F, Tanrıverdi H, Uygur F, Örnek T, Atalay F, et al. Syncope as a presentation of acute pulmonary embolism. Ther Clin Risk Manag. 2016;12:1023–8. Available from: https://doi.org/10.2147/TCRM.S105722.

143.

Duplyakov D, Kurakina E, Pavlova T, Khokhlunov S, Surkova E. Value of syncope in patients with high-to-intermediate risk pulmonary artery embolism. Eur Heart J Acute Cardiovasc Care. 2015;4:353–8. Available from: https://doi.org/10.1177/2048872614527837.

144.

Huang C-M, Lin Y-C, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, et al. Risk stratification and clinical outcomes in patients with acute pulmonary embolism. Clin Biochem. 2011;44:1110–5. Available from: https://doi.org/10.1016/j.clinbiochem.2011.06.077.

145.

Calvo-Romero JM, Pérez-Miranda M, Bureo-Dacal P. Syncope in acute pulmonary embolism. Eur J Emerg Med. 2004;11:208–9. Available from: https://doi.org/10.1097/01.mej.0000136696.49343.8f.

146.

Jiménez D, Díaz G, Valle M, Martí D, Escobar C, Vidal R, et al. Prognostic value of syncope in the presentation of pulmonary embolism. Arch Bronconeumol. 2005;41:385–8. Available from: https://doi.org/10.1016/s1579-2129(06)60246-2.

147.

Jenab Y, Lotfi-Tokaldany M, Alemzadeh-Ansari M-J, Seyyedi SR, Shirani S, Soudaee M, et al. Correlates of syncope in patients with acute pulmonary thromboembolism. Clin Appl Thromb Hemost. 2015;21:772–6. Available from: https://doi.org/10.1177/1076029614540037.

148.

Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386–9. Available from: https://doi.org/10.1016/s0140-6736(98)07534-5.

149.

•• Barco S, Ende-Verhaar YM, Becattini C, Jimenez D, Lankeit M, Huisman MV, et al. Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2018;39:4186–95. Available from: https://doi.org/10.1093/eurheartj/ehy631. In this meta-analysis, the authors described various studies which found the association between syncope and PE versus those which didn't. Syncope had shown a higher prevalence of hemodynamic instability, echocardiographic changes along with higher prevalence of mortality.

150.

Collado A, Villalta J, Bombí JA, Ingelmo M. Diagnostic and prognostic value of factors associated with pulmonary thromboembolism. Study of 70 autopsy cases. Med Clin. 1986;86:265–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/3713341.

151.

Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med. 1982;73:822–6. Available from: https://doi.org/10.1016/0002-9343(82)90764-1.

152.

Sarasin FP, Louis-Simonet M, Carballo D, Slama S, Rajeswaran A, Metzger JT, et al. Prospective evaluation of patients with syncope: a population-based study. Am J Med. 2001;111:177–84. Available from: https://doi.org/10.1016/s0002-9343(01)00797-5.

153.

Freund Y, Philippon AL, Feral-Pierssens AL, Damas Perrichet C, Boussouar S, Donciu V, et al. Prevalence of pulmonary embolism in patients with isolated syncope in the emergency department: the PEEPS multicenter prospective cohort study. Pulmonary embolism. European Respiratory Society; 2019. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.congress-2019.PA3645.

154.

Richmond C, Jolly H, Isles C. Syncope in pulmonary embolism: a retrospective cohort study. Postgrad Med J. 2020. Available from: https://doi.org/10.1136/postgradmedj-2020-138677.

155.

Ghuysen A, Ghaye B, Willems V, Lambermont B, Gerard P, Dondelinger RF, et al. Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism. Thorax. 2005;60:956–61. Available from: https://doi.org/10.1136/thx.2005.040873.

156.

Meneveau N, Ming LP, Séronde MF, Mersin N, Schiele F, Caulfield F, et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J. 2003;24:1447–54. Available from: https://doi.org/10.1016/s0195-668x(03)00307-5.

157.

Fred HL, Yang M. Sudden loss of consciousness, dyspnea, and hypoxemia in a previously healthy young man. Circulation. 1995. Available from: https://doi.org/10.1161/01.CIR.91.12.3017.

158.

Marine JE, Goldhaber SZ. Pulmonary embolism presenting as seizures. Chest. 1997. Available from: https://doi.org/10.1378/chest.112.3.840.

159.

Kupnik D, Grmec Š. Pulmonary thromboembolism presenting as epileptiform generalized seizure. Eur J Emerg Med. 2004. Available from: https://doi.org/10.1097/00063110-200412000-00009.

160.

Volz EEG, Jasani N. Seizure as a presentation of pulmonary embolism. J Emerg Med. 2014. Available from: https://doi.org/10.1016/j.jemermed.2013.08.057.

161.

•• Zuin M, Rigatelli G, Zuliani G, Adami A, Zonzin P, Roncon L. Seizures as the first clinical manifestation of acute pulmonary embolism: an underestimate issue in neurocritical care. Neurol Sci. 2020. Available from: https://doi.org/10.1007/s10072-020-04275-y. A literature review of 258 articles analyzing pathophysiology, clinical presentation, treatment, and outcomes for patients with concomitant seizure and pulmonary embolism.

162.

Pourshahid S, Dedhia S, Hakim S, Barakat M, Genin D. Seizure and Pulmonary Embolism: A Differential That Can Save a Life. Case Rep Pulmonol. 2017. Available from: https://doi.org/10.1155/2017/3408795.

163.

Kimura K, Mori H, Kitaguchi H, Yamao F, Shindo K. Pulmonary embolism as a cause of seizure. Am J Emerg Med. 2013. Available from: https://doi.org/10.1016/j.ajem.2013.06.024.

164.

Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH. Post-thrombotic syndrome: a clinical review. J Thromb Haemost. 2013;11:795–805. Available from: https://doi.org/10.1111/jth.12180.

165.

Langeron P. Painful manifestations of the sequelae of phlebitis. Phlebologie. 1992;45:51–8; discussion 59-60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1496032.

166.

Sahu KK, Mishra AK, Zhang P. Femoral Neuropathy: A Rare Presentation of Retroperitoneal Hematoma with Review of Literature. Indian J Hematol Blood Transfus. 2020;36:174–7. Available from: https://doi.org/10.1007/s12288-019-01126-5.

167.

Qureshi AI, Babar S, Kherani D, Saleem MA, Qi L, Wallery SS, et al. Femoral Neuropathy Following Transfemoral Neuroendovascular Procedures. An Analysis of a Prospective Registry. J Neuroimaging. 2019;29:268–71. Available from: https://doi.org/10.1111/jon.12584.

168.

Bendszus M, Reiners K, Perez J, Solymosi L, Koltzenburg M. Peroneal nerve palsy caused by thrombosis of crural veins. Neurology. 2002;58:1675–7. Available from: https://doi.org/10.1212/wnl.58.11.1675.

169.

Hufeland M, Braun M, Marnitz T, Schroeder J, Lindner T. Peroneal nerve palsy due to thrombosis of a crural vein in a healthy young woman. Clin Neurol Neurosurg. 2013;115:487–9. Available from: https://doi.org/10.1016/j.clineuro.2012.06.012.

170.

Bayramoglu A, Calmasur A, Akoz A, Saritemur M. A Rare Cause of Compression of the Ulnar Nerve Neuritis: Deep Vein Thrombosis. Turk J Emerg Med. 2014;14:97. Available from: https://doi.org/10.5505/1304.7361.2014.59319.

171.

Nkele C. Acute carpal tunnel syndrome resulting from haemorrhage into the carpal tunnel in a patient on warfarin. J Hand Surg Br. 1986;11:455–6. Available from: https://doi.org/10.1016/0266-7681(86)90181-6.

Titel: Neurological Complications of Pulmonary Embolism: a Literature Review
verfasst von: Parth V. Desai
Nicolas Krepostman
Matthew Collins
Sovik De Sirkar
Alexa Hinkleman
Kevin Walsh
Jawed Fareed
Amir Darki
Publikationsdatum: 01.10.2021
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 10/2021
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01145-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Dietary Insights in Neurological Diseases

Current Understanding of the Pathophysiology and Approach to Tension-Type Headache

The Ties that Bind: Agnosia, Neglect and Selective Attention to Visual Scale

Medical and Neurological Management of Brain Tumor Complications

Color Vision Deficits